PLCB1

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 · Q9NQ66 · PLCB1 on Sugi Atlas →

501 patent compounds predicted against PLCB1, 271 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL179741 SCHEMBL179741 1.00 1/20
SCHEMBL235442 SCHEMBL235442 1.00 1/20
SCHEMBL481144 SCHEMBL481144 1.00 1/20
SCHEMBL719389 SCHEMBL719389 1.00 1/20
SCHEMBL935371 SCHEMBL935371 1.00 1/20
SCHEMBL2157698 SCHEMBL2157698 1.00 1/20
SCHEMBL3125919 SCHEMBL3125919 1.00 1/20
SCHEMBL4835874 SCHEMBL4835874 1.00 1/20
SCHEMBL2916853 SCHEMBL2916853 0.78 1/20
SCHEMBL4835681 SCHEMBL4835681 0.78 1/20
SCHEMBL7271016 SCHEMBL7271016 0.78 1/20
SCHEMBL27595459 SCHEMBL27595459 0.76 1/20
SCHEMBL1063416 SCHEMBL1063416 0.68 1/20
SCHEMBL1064244 SCHEMBL1064244 0.68 1/20
SCHEMBL1263461 SCHEMBL1263461 0.68 1/20
Glutamic Acid Glutamic Acid (SCHEMBL5183929) 0.64 1/20
SCHEMBL2809553 SCHEMBL2809553 0.61 1/20
SCHEMBL7924516 SCHEMBL7924516 0.61 1/20
SCHEMBL29952657 SCHEMBL29952657 0.61 1/20
SCHEMBL29952939 SCHEMBL29952939 0.61 1/20

Clinical trials — most relevant to PLCB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial PHASE2/PHASE3UNKNOWN
Inositol in Letrozol Resistant PCOS Women PHASE2/PHASE3COMPLETED
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Molecular Markers of Human Sperm Function nanWITHDRAWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity. nanUNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Clinical Characteristics of Primary Liver Cancer nanUNKNOWN
Candida Associated Cytokines in Oral Leukoplakia nanCOMPLETED
Plaque Calcium Characterization and Ruptured Plaques nanUNKNOWN
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
Liver Cancer Prognosis Investigation Study nanNOT_YET_RECRUITING
Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential nanNOT_YET_RECRUITING
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations nanWITHDRAWN
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome nanCOMPLETED
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PLCB1 binder may also engage these)

ProteinNameSimilarity
P10687 1.000 P10687 →
Q9Z1B3 1.000 Q9Z1B3 →
P10894 1.000 P10894 →
Q9QW07 0.996 Q9QW07 →
Q07722 0.993 Q07722 →
Q9UPR0 0.992 Q9UPR0 →
Q8K394 0.992 Q8K394 →
P51432 0.991 P51432 →
Q15147 0.990 Q15147 →
P25455 0.987 P25455 →
G5EBH0 0.984 G5EBH0 →
PLCB3 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 0.984 landscape →
Q99JE6 0.983 Q99JE6 →
Q8BPM2 0.983 Q8BPM2 →
Q62688 0.982 Q62688 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.982 landscape →
B4F7E7 0.981 B4F7E7 →
Q15111 0.980 Q15111 →
Q3USB7 0.980 Q3USB7 →
Q32NH8 0.979 Q32NH8 →
Q4KWH8 0.977 Q4KWH8 →
A4IID4 0.977 A4IID4 →
Q9H8V3 0.976 Q9H8V3 →
Q07139 0.976 Q07139 →
Q5ZLV4 0.976 Q5ZLV4 →
Q7ZY60 0.976 Q7ZY60 →
A2APV2 0.976 A2APV2 →
PI4KB Phosphatidylinositol 4-kinase beta 0.976 landscape →
Q9ESF1 0.975 Q9ESF1 →
Q5SPC5 0.975 Q5SPC5 →